Summary
A large clinical study, designed to investigate the induction of theophylline metabolism by phenytoin, provided the opportunity to test a previously proposed method for estimating dose requirements of phenytoin. This method involves prediction of the oral maintenance dosage from data obtained following the administration of an intravenous loading dose.
In 30 subjects, trough plasma concentration at steady-state were 12.0±4.9 µg·ml−1 (mean ±SD) and differed by −2.7±39.3% from a mean target plasma concentration of 12.5±1.5µg·ml−1.
A Bayesian regression programme was used to forecast an estimate of each subject's individual pharmacokinetics. These were then used to predict the steady-state plasma concentrations which would be expected from a standard dosing regimen (4 mg per kg per day). When compared to the results expected from the use of this standard dosage, the proposed method gave acceptable steady-state plasma phenytoin concentrations with significant reductions in deviations from target concentrations.
This method for the rapid individualization of phenytoin dosage requirements provides an improvement over more traditional methods of choosing an arbitrary dose adjusted for body weight followed by dosage adjustments based on achieved plasma concentration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benet LZ, Sheiner LB (1985) Appendix II. Design and optimization of dosage regimens; pharmacokinetic data. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) Goodman and Gilmans's. The pharmacological basis of therapeutics. 7th ed. Macmillan, New York, pp 1663–1733
Crowley JJ, Cusack BJ, Jue SG, Koup JR, Vestal RE (1986a) Effect of smoking and phenytoin on theophylline metabolism in healthy young adults. Clin Res 34: 90A
Crowley JJ, Cusack BJ, Jue SG, Koup JR, Vestal RE (1986b) Induction of theophylline metabolism by phenytoin is unaltered by aging. Clin Res 34: 396A
Grasela TH, Sheiner LB, Rambeck B et al. (1983) Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 8: 355–364
Jusko WJ, Koup JR, Alvan G (1976) Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm 4: 327–336
Koup JR, Benjamin DR (1980) Numerical integration simulation program for the microcomputer. Ther Drug Monit 2: 243–247
Koup JR, Gibaldi M, Godolphin W (1981) Single point estimation of phenytoin dosing: a reappraisal. Res Commun Chem Pathol Pharmacol 34: 231–239
Liponi DF, Winter ME, Toxer TN (1984) Renal function and therapeutic concentrations of phenytoin. Neurology 34: 395–397
Ludden TM, Beal SL, Peck CC, Godley PJ (1986) Interpretation of phenytoin concentration-time data using Bayesian regression analysis: An initial evaluation. Clin Pharm 5: 580–585
Oellerich M (1980) Enzyme immunoassays in clinical chemistry: Present status and trends. J Clin Chem Clin Biochem 18: 197–208
Sawchuck RJ, Zaske DE (1976) Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J Pharmacokinet Biopharm 4: 183–195
Tozer TN, Winter ME (1980) Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: Principles of therapeutic drug monitoring. Applied Therapeutics Inc, San Francisco, pp 275–314
Vozeh S, Muir KT, Sheiner LB, Follath F (1981) Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 9: 131–147
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Crowley, J.J., Koup, J.R., Cusack, B.J. et al. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. Eur J Clin Pharmacol 32, 141–148 (1987). https://doi.org/10.1007/BF00542186
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542186